Abstract
The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are the most commonly used scales to test cognitive impairment in Lewy body disease (LBD), but there is no consensus on which is best suited to assess cognition in clinical practice and most sensitive to cognitive decline. Retrospective cohort study of 265 LBD patients [Parkinson’s disease (PD) without dementia (PDnD, N = 197), PD with dementia (PDD, N = 40), and dementia with Lewy bodies (DLB, N = 28)] from an international consortium who completed both the MMSE and MoCA at baseline and 1-year follow-up (N = 153). Percentage of relative standard deviation (RSD%) at baseline was the measure of inter-individual variance, and estimation of change (Cohen’s d) over time was calculated. RSD% for the MoCA (21 %) was greater than for the MMSE (13 %) (p = 0.03) in the whole group. This difference was significant only in PDnD (11 vs. 5 %, p < 0.01), but not in PDD (30 vs. 19 %, p = 0.37) or DLB (15 vs. 14 %, p = 0.78). In contrast, the 1-year estimation of change did not differ between the two tests in any of the groups (Cohen’s effect <0.20 in each group). MMSE and MoCA are equal in measuring the rate of cognitive changes over time in LBD. However, in PDnD, the MoCA is a better measure of cognitive status as it lacks both ceiling and floor effects.
Similar content being viewed by others
References
Aarsland D, Andersen K, Larsen JP, Perry R, Wentzel-Larsen T, Lolk A, Kragh-Sorensen P (2004) The rate of cognitive decline in Parkinson disease. Arch Neurol 61:1906–1911
Aarsland D, Beyer MK, Kurz MW (2008) Dementia in Parkinson’s disease. Curr Opin Neurol 21:676–682
Aarsland D, Muniz G, Matthews F (2011a) Nonlinear decline of mini-mental state examination in Parkinson’s disease. Mov Disord 26:334–337
Aarsland D, Muniz G, Matthews F (2011b) Nonlinear decline of mini-mental state examination in Parkinson’s disease. Mov Disord 26:334–337
Biundo R, Weis L, Facchini S, Formento-Dojot P, Vallelunga A, Pilleri M, Antonini A (2014) Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia. Parkinsonism Relat Disord 20:394–399
Bland JM, Altman DG (1995) Comparing two methods of clinical measurement: a personal history. Int J Epidemiol 24(Suppl 1):S7–S14
Breitve MH, Chwiszczuk LJ, Hynninen MJ, Rongve A, Bronnick K, Janvin C, Aarsland D (2014) A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer’s disease. Alzheimers Res Ther 6:53-014-0053-6 (eCollection 2014)
Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Troster AI, Uc EY, Parkinson Study Group Cognitive/Psychiatric Working Group (2010) A recommended scale for cognitive screening in clinical trials of Parkinson’s disease. Mov Disord 25:2501–2507
Chou KL, Lenhart A, Koeppe RA, Bohnen NI (2014) Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates. Parkinsonism Relat Disord 20:1076–1080
Cohen J (1988) Statistical power analysis for the behavioral sciences. L. Erlbaum Associates, Hillsdale
Dalrymple-Alford JC, Livingston L, MacAskill MR, Graham C, Melzer TR, Porter RJ, Watts R, Anderson TJ (2011) Characterizing mild cognitive impairment in Parkinson’s disease. Mov Disord 26:629–636
Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324
Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39
Gill DJ, Freshman A, Blender JA, Ravina B (2008) The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson’s disease. Mov Disord 23:1043–1046
Glatt SL, Hubble JP, Lyons K, Paolo A, Troster AI, Hassanein RE, Koller WC (1996) Risk factors for dementia in Parkinson’s disease: effect of education. Neuroepidemiology 15:20–25
Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, Weintraub D (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73:1738–1745
Hu MT, Szewczyk-Krolikowski K, Tomlinson P, Nithi K, Rolinski M, Murray C, Talbot K, Ebmeier KP, Mackay CE, Ben-Shlomo Y (2014) Predictors of cognitive impairment in an early stage Parkinson’s disease cohort. Mov Disord 29:351–359
Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, Spokes EG (2000) A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 54:1596–1602
Kandiah N, Zhang A, Cenina AR, Au WL, Nadkarni N, Tan LC (2014) Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson’s disease. Parkinsonism Relat Disord 20:1145–1148
Kelley K (2007) Sample size planning for the coefficient of variation from the accuracy in parameter estimation approach. Behav Res Methods 39:755–766
Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA (2010) Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis 19:1401–1408
Lessig S, Nie D, Xu R, Corey-Bloom J (2012a) Changes on brief cognitive instruments over time in Parkinson’s disease. Mov Disord 27:1125–1128
Lessig S, Nie D, Xu R, Corey-Bloom J (2012b) Changes on brief cognitive instruments over time in Parkinson’s disease. Mov Disord 27:1125–1128
Levy G, Schupf N, Tang MX, Cote LJ, Louis ED, Mejia H, Stern Y, Marder K (2002) Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Ann Neurol 51:722–729
Malek-Ahmadi M, Powell JJ, Belden CM, O’Connor K, Evans L, Coon DW, Nieri W (2015) Age- and education-adjusted normative data for the Montreal Cognitive Assessment (MoCA) in older adults age 70–99. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 22:755–761
McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M, Consortium on DLB (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872
Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699
Nelson PT, Jicha GA, Kryscio RJ, Abner EL, Schmitt FA, Cooper G, Xu LO, Smith CD, Markesbery WR (2010) Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol 257:359–366
Oesterhus R, Soennesyn H, Rongve A, Ballard C, Aarsland D, Vossius C (2014) Long-term mortality in a cohort of home-dwelling elderly with mild Alzheimer’s disease and Lewy body dementia. Dement Geriatr Cogn Disord 38:161–169
Owen AM (2004) Cognitive dysfunction in Parkinson’s disease: the role of frontostriatal circuitry. Neuroscientist 10:525–537
Richardson JTE (2011) The analysis of 2 × 2 contingency tables—Yet again. Stat Med 30:890
Rongve A, Vossius C, Nore S, Testad I, Aarsland D (2014) Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer’s dementia. Int J Geriatr Psychiatry 29:392–398
Santangelo G, Siciliano M, Pedone R, Vitale C, Falco F, Bisogno R, Siano P, Barone P, Grossi D, Santangelo F, Trojano L (2015) Normative data for the Montreal Cognitive Assessment in an Italian population sample. Neurol Sci 36:585–591
Temlett JA, Thompson PD (2006) Reasons for admission to hospital for Parkinson’s disease. Intern Med J 36:524–526
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653
van Steenoven I, Aarsland D, Hurtig H, Chen-Plotkin A, Duda JE, Rick J, Chahine LM, Dahodwala N, Trojanowski JQ, Roalf DR, Moberg PJ, Weintraub D (2014) Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale-2 scores in Parkinson’s disease. Mov Disord 29:1809–1815
Verghese J, Crystal HA, Dickson DW, Lipton RB (1999) Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 53:1974–1982
Wang CS, Pai MC, Chen PL, Hou NT, Chien PF, Huang YC (2013) Montreal Cognitive Assessment and Mini-Mental State Examination performance in patients with mild-to-moderate dementia with Lewy bodies, Alzheimer’s disease, and normal participants in Taiwan. Int Psychogeriatr 25:1839–1848
Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, Wang C, Tan MS, Tan L (2015) Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 86:135–143
Zadikoff C, Fox SH, Tang-Wai DF, Thomsen T, de Bie RM, Wadia P, Miyasaki J, Duff-Canning S, Lang AE, Marras C (2008) A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson’s disease. Mov Disord 23:297–299
Acknowledgments
We are thankful to Pablo Martinez-Martin for helping with statistical analysis
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
All authors gave final approval of this version of the manuscript to be published. We can assure that there is no one else who fulfils the criteria but has not been included as an author.
Funding
This working group is funded by the Research Council of Norway, Norway under the aegis of JPND.
Conflict of interest
The authors have no competing interest to declare.
Additional information
On behalf of the DLB consortium.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Biundo, R., Weis, L., Bostantjopoulou, S. et al. MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. J Neural Transm 123, 431–438 (2016). https://doi.org/10.1007/s00702-016-1517-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-016-1517-6